What is Rxsight?
Founded in 1997 and headquartered in California, RxSight operates at the intersection of advanced optics and clinical precision. The company specializes in the development of adjustable IOL technology, which allows physicians to predictably optimize a patient's vision after cataract surgery. By providing a non-invasive, office-based solution, RxSight addresses a critical market need for personalized visual outcomes, positioning itself as a leader in the high-growth medical technology sector.
How much funding has Rxsight raised?
Rxsight has raised a total of $317.8M across 7 funding rounds:
Private Equity
$8.5M
Private Equity
$12.7M
Debt
$17M
Private Equity
$52M
Private Equity
$50M
Debt
$60M
Share Placement
$117.6M
Private Equity (2009): $8.5M, investors not publicly disclosed
Private Equity (2011): $12.7M, investors not publicly disclosed
Debt (2015): $17M, investors not publicly disclosed
Private Equity (2015): $52M featuring RA Capital Management, Longitude Capital, H.I.G. BioVentures, and Balance Point Capital
Private Equity (2017): $50M, investors not publicly disclosed
Debt (2020): $60M with participation from Oxford Finance
Share Placement (2021): $117.6M, investors not publicly disclosed
Key Investors in Rxsight
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
H.I.G. BioVentures
H.I.G. Capital is a global alternative investment firm that specializes in private equity, growth equity, and private credit, providing capital and operational expertise to support long-term growth across various healthcare sectors.
Oxford Finance
Oxford Finance is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide, supporting innovation through tailored debt and capital structures.
What's next for Rxsight?
With the support of this major enterprise-level funding, RxSight is well-positioned to scale its commercial operations and expand the clinical adoption of its light-adjustable lens technology. The strategic allocation of these resources will likely focus on accelerating market penetration, enhancing research and development pipelines, and strengthening the company's infrastructure to support long-term growth in the global healthcare market. As the firm continues to refine its clinical offerings, it remains a key player to watch for further advancements in refractive surgery solutions.
See full Rxsight company page
